[
  {
    "ts": null,
    "headline": "AbbVie cuts 2024 profit forecast on acquisition expenses",
    "summary": "AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year. To that end, AbbVie bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.",
    "url": "https://finnhub.io/api/news?id=4fe1f2396c202057a8b1226f7b0e7f91aca770d4dd34ccb0514a5dace6bb84e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736199934,
      "headline": "AbbVie cuts 2024 profit forecast on acquisition expenses",
      "id": 132292397,
      "image": "https://media.zenfs.com/en/reuters-finance.com/a5d646cf3aee1ecd7f67cffe3989f9c6",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year. To that end, AbbVie bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.",
      "url": "https://finnhub.io/api/news?id=4fe1f2396c202057a8b1226f7b0e7f91aca770d4dd34ccb0514a5dace6bb84e3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=836342c7229c9efc01a40c444363089c0345c44d9a1c9d8befc96ea0463fcc66",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736181240,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 132322050,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=836342c7229c9efc01a40c444363089c0345c44d9a1c9d8befc96ea0463fcc66"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call",
    "summary": "NORTH CHICAGO - AbbVie will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens.AbbVie will host a live webcast of the earnings...",
    "url": "https://finnhub.io/api/news?id=5ae070b5b56c8df842b3e198fa968272c3090b02382f5208dbb8f1f2f9266e8c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736161218,
      "headline": "AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call",
      "id": 132287139,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO - AbbVie will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens.AbbVie will host a live webcast of the earnings...",
      "url": "https://finnhub.io/api/news?id=5ae070b5b56c8df842b3e198fa968272c3090b02382f5208dbb8f1f2f9266e8c"
    }
  },
  {
    "ts": null,
    "headline": "The Smartest Dividend Stocks to Buy With $500 Right Now",
    "summary": "Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.",
    "url": "https://finnhub.io/api/news?id=1f9a0624e04c8f5f030062fb4a1319ec11ac73e7fc8849719b36c9588b051fb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736160300,
      "headline": "The Smartest Dividend Stocks to Buy With $500 Right Now",
      "id": 132286160,
      "image": "https://g.foolcdn.com/editorial/images/802630/dividend-growth-investing.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.",
      "url": "https://finnhub.io/api/news?id=1f9a0624e04c8f5f030062fb4a1319ec11ac73e7fc8849719b36c9588b051fb7"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Dividend Stocks to Buy With $250 in 2025",
    "summary": "When it comes to dividend investing, there are two basic paths you can take.  If you can't decide which dividend investing option you like best, I have some great news.  AbbVie has been a long-term dividend investor's dream come true since it split from Abbott Laboratories in 2013.",
    "url": "https://finnhub.io/api/news?id=7c1ffd5066eeb9cb6a27be45496a443a5e00e34124b75be5a2b2e689450046d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736155020,
      "headline": "2 No-Brainer Dividend Stocks to Buy With $250 in 2025",
      "id": 132284147,
      "image": "https://g.foolcdn.com/editorial/images/802887/individual-investors-at-home-getty.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "When it comes to dividend investing, there are two basic paths you can take.  If you can't decide which dividend investing option you like best, I have some great news.  AbbVie has been a long-term dividend investor's dream come true since it split from Abbott Laboratories in 2013.",
      "url": "https://finnhub.io/api/news?id=7c1ffd5066eeb9cb6a27be45496a443a5e00e34124b75be5a2b2e689450046d1"
    }
  }
]